论文部分内容阅读
目的:探讨舌下特异性免疫治疗(SLIT)对于儿童过敏性支气管哮喘的疗效。方法:将72例儿童过敏性支气管哮喘患儿随机分成两组各36例,治疗组在吸入低剂量糖皮质激素(相当于200μg布地奈德等效剂量)的基础上加用舌下含服粉尘螨滴剂治疗,对照组单纯吸入低剂量糖皮质激素,疗程均为18个月。观察两组在治疗期间人均累计哮喘急性发作次数、人均每次哮喘急性发作持续天数、夜间症状评分、治疗前后血清总IgE指标及肺通气功能第1秒时间肺活量(FEV1)、最大呼气流速(PEF)共6项指标。结果:人均累计哮喘急性发作次数比较(P<0.01)、人均每次哮喘急性发作天数比较(P<0.01)、夜间症状评分比较(P<0.05)、FEV1比较(P<0.01)、PEF比较(P<0.05)、血清总IgE比较(P<0.01),治疗组各项指标均优于对照组,差异均有统计学意义。结论:特异性免疫治疗舌下含服粉尘螨滴剂治疗儿童过敏性哮喘疗效显著。
Objective: To investigate the effect of sublingual immunotherapy (SLIT) on children with allergic bronchial asthma. Methods: Seventy-two children with allergic bronchial asthma were randomly divided into two groups (n = 36). The treatment group was treated with inhaled low dose glucocorticoid (equivalent to 200 μg budesonide equivalent dose) with sublingual buildup Mite drops treatment, the control group simply inhaled low-dose glucocorticoid, treatment were 18 months. The number of acute exacerbations, the duration of acute exacerbation per asthma per patient, the score of nocturnal symptoms, the total serum IgE before and after treatment and the first second lung function (FEV1), the maximum expiratory flow rate ( PEF) a total of six indicators. Results: The number of acute asthma exacerbations per capita was compared (P <0.01), the number of acute exacerbation per asthma per day (P <0.01), night symptom scores (P <0.05), FEV1 (P <0.01) P <0.05), serum total IgE (P <0.01), the treatment group indicators were better than the control group, the differences were statistically significant. Conclusion: Specific immunotherapy sublingual powder dust mite drops treatment of children with allergic asthma significant effect.